Metamizole
ApprovedSmall molecule
Boehringer IngelheimMetamizole is one of 102 small molecule programs targeting Cancer Pain. It is currently in Approved.
3
Indications
12
Total Trials
2
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
430 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Metamizole
Boehringer IngelheimApproved
Repatha
AmgenPreclinical
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Tylenol
KKenvue Brands
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Statins
SanofiPreclinical
Urokinase
Mmedac GmbH
Preclinical
Drug Therapy
MMassachusetts General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment2 trials
Oncology Patients1 trial
Post Operative Pain1 trial
Postoperative Pain in Scheduled Craniotomy
Completed·—··NCT04720248·73 enrolled
6 more indications
Ischemic stroke1 trial
Analgesia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metamizole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company